- Research article
- Open Access
Long-term neprilysin gene transfer is associated with reduced levels of intracellular Abeta and behavioral improvement in APP transgenic mice
© Spencer et al; licensee BioMed Central Ltd. 2008
- Received: 18 June 2008
- Accepted: 12 November 2008
- Published: 12 November 2008
Proteolytic degradation has emerged as a key pathway involved in controlling levels of the Alzheimer's disease (AD)-associated amyloid-β (Aβ) peptide in the brain. The endopeptidase, neprilysin, has been implicated as a major Aβ degrading enzyme in mice and humans. Previous short and intermediate term studies have shown the potential therapeutic application of neprilysin by delivering this enzyme into the brain of APP transgenic mice using gene transfer with viral vectors. However the effects of long-term neprilysin gene transfer on other aspects of Aβ associated pathology have not been explored yet in APP transgenic mice.
We show that the sustained expression of neprilysin for up to 6 months lowered not only the amyloid plaque load but also reduced the levels of intracellular Aβ immunoreactivity. This was associated with improved behavioral performance in the water maze and ameliorated the dendritic and synaptic pathology in the APP transgenic mice.
These data support the possibility that long-term neprilysin gene therapy improves behavioral and neurodegenerative pathology by reducing intracellular Aβ.
- Water Maze
- Amyloid Precursor Protein
- Vibratome Section
- Neurodegenerative Pathology
- Tyramide Signal Amplification
Alzheimer's disease (AD) is a progressive neurodegenerative disorder affecting the elderly and is the most common form of dementia . Synaptic pathology is an early indicator of neurodegeneration in the brains of patients with AD [2–4] and in amyloid precursor protein (APP) transgenic (tg) mice . Damage to the nerve terminals is strongly correlated with the severity of the cognitive impairment in patients with AD [2–4]. A key mediator of this disease is believed to be the accumulation of amyloid-β (Aβ) peptides, produced by proteolytic processing of the APP, in the central nervous system . Most recent studies indicate that Aβ oligomers rather than fibrils are responsible for the synaptic pathology in AD [7–9] and other lines of investigation also support a role for intraneuronal accumulation of Aβ in neurodegeneration [10–13].
Extracellular and intracellular accumulation of Aβ peptides might result from alterations in the balance between production, aggregation and degradation . Mutations in the APP and presenillin-1 (PS1) genes have been found to be associated with familial/heritable forms of early-onset AD by increasing the production of Aβ peptides, which has greatly added to our understanding of potential mechanisms leading to aberrant anabolism of Aβ [15–19]. However, the mechanisms of catabolism and clearance of Aβ are less well understood. Endopeptidases, which directly degrade Aβ, have emerged as important players in the homeostatic control of this peptide. Neprilysin (NEP or EC 22.214.171.124) is a zinc metalloendopeptidase that can degrade Aβ , and has been identified as a critical Aβ degrading enzyme in the brain [21, 22]. Several groups have also reported an inverse correlation between the presence of NEP at the protein or RNA levels and vulnerability to amyloid deposition in both mice and humans [23–30].
The genetic linkage of the NEP gene to AD is currently unclear as several groups have reported no association [31, 32], while more have identified an association with the disease [33–36]. Furthermore, chemical inhibition of NEP was shown to result in rapid accumulation of Aβ and pathological deposition in rodents [21, 37]. Previously we and other groups have shown that the overexpression of NEP in APP tg mice by gene transfer [38–41], transgenesis , or induction  resulted in a reduction of Aβ accumulation, neurodegeneration and behavioral deficits. Moreover, the upregulation of NEP by somatostatin or by environmental enrichment has been reported to reduce Aβ levels in vitro and in vivo [44, 45]. Conversely, reduced NEP expression results in amyloid plaque deposition and amyloid angiopathy  as well as accumulation of Aβ in the synapses and behavioural deficits .
These findings outline the potential application of NEP augmentation to treat AD. However, most previous gene transfer studies with NEP have been for short or intermediate periods of time [38–40, 48, 49] and the effects of long-term NEP gene transfer on other aspects of Aβ-associated pathology need to be explored in APP tg mice. Among them, recent evidence suggests that accumulation of intracellular Aβ might also play a role in neurodegeneration in transgenic models and in AD [10–13]. We show that the sustained expression of NEP with a lentiviral vector (LV) for up to 6 months, in addition to lowering the amyloid plaque load, reduced the levels of intracellular Aβ immunoreactivity. This was associated with improved behavioral performance in the water maze and ameliorated the dendritic and synaptic pathology in the APP tg mice. These data support the possibility that long-term NEP gene therapy improves behavioral and neurodegenerative pathology by reducing intracellular Aβ.
Long-term neprilysin gene transfer reduces the accumulation of intracellular Aβ
Long-term treatment with LV-NEP ameliorates water maze deficits in APP tg mice
The effects of LV-NEP on water maze performance and neurodegeneration are associated with reduced intracellular Aβ accumulation
The present study showed that long-term gene therapy with LV-NEP for up to 6 months improved behavioral performance and ameliorated the dendritic and synaptic pathology in APP tg mice by reducing the levels of intracellular Aβ immunoreactivity. Previous studies have been focused at analyzing the short-term effects (1 month) of NEP in behavioral deficits and amyloid accumulation in APP tg mice. These studies have shown that delivery of NEP into the hippocampus of APP tg mice by LV, adenoviral-associated viral vectors (AAV) or herpes simplex viral (HSV) vectors can reduce numbers of plaques as well as overall Aβ levels in the CNS [38, 39, 48, 49]. AAV delivered Nep showed localization of the protein at the presynaptic sites whereas with the lentivirus we observed localization to the cell soma and the ER. The reason for this difference in cellular localization is not clear, however it may have to do with the presence of the WPRE translation signal present in the lentivirus vector we used that was not used in the AAV experiments . Similar protein localization differences have been observed for GFP when comparing these two vectors .
The vector-delivered NEP resulted in behavioral improvements in the mice. In addition to these studies, recent studies where LV-NEP was delivered into the hippocampus of 3-month old mice showed a reduction in plaques and overall Aβ levels in the CNS as well as improvements in behavior after 4 months . The latter study was performed in mPrP-APP695 mutant mice crossed to presenilin 1 mutant mice . These mice develop plaques and accumulate Aβ at a much greater rate than previous mouse models utilized in the field. For the present study we utilized a more clinically relevant APP tg mouse model . Although mice do not develop the full spectrum of AD, they mimic the human disease in that they develop plaques and display Aβ accumulation and age-dependent synaptic pathology [5, 56] and behavioral deficits at a slower rate compared to a recent study .
The effects of neprilysin gene therapy might be reflected in a number of compartments, not only in the extracellular Aβ. Although the intracellular pool might represent a small proportion of the total Aβ it might be important in terms of mediating neuronal cell damage [10–13]. The reduction of intracellular Aβ could also be related to a reduction of the extracellular Aβ, with less being endocytosed. In contrast to previous studies that focused on the numbers of plaques and total accumulated levels of Aβ [38, 39, 48, 49, 54], we focused our study on the levels of intracellular Aβ. While some studies have suggested that post-transcriptionally-modified Aβ fragments  and oligomers [7–9] might be responsible for the neurotoxic effects, others have suggested that accumulation of intracellular Aβ might also play a role [10–13]. This is a concern because recent evidence suggests that accumulation of intracellular Aβ may play a role in neuronal dysfunction and degeneration by disturbing ERK-CREB signalling and increasing intracellular calcium levels [12, 58].
We found that levels of intracellular Aβ were reduced in areas where the LV-NEP was injected. Moreover, the reduction in intracellular Aβ immunoreactivity correlated with the improved behavioral performance in the mice. This is consistent with a study in Drosophila that showed that overexpression of NEP reduces the pathology associated with tg expression of intracellular Aβ1–42 . The mechanisms through which NEP might reduce intracellular Aβ are not clear, however NEP is a membrane-bound enzyme that is distributed both in the plasma membrane and endo-membrane system . Thus, interactions might occur at the endoplasmic reticulum where previous studies have shown that intracellular Aβ accumulates [10–13].
It has become increasingly clear in recent years that NEP may be an important player in the treatment of AD. Several genetic linkage studies have now reported an association between NEP polymorphisms and risk for AD [33–36]. Furthermore, a potential mechanism has been identified by which NEP down-regulation with age can increase vulnerability to amyloid pathology via reduced levels of somatostatin . In addition, NEP levels and activity are significantly reduced in the brains of AD patients [30, 61–63]. Therefore, replacement therapy might require long-term NEP delivery, which might raise concerns about possible toxic effects. For this reason, we extended our studies to a 6-month duration of therapy. It is important to emphasize that compared to others, in our study injections were placed both in the hippocampus and neocortex and we also analyzed the integrity of the neuronal structure with antibodies against synaptophysin and MAP2.
The present study confirmed that long-term LV-NEP ameliorated the neurodegenerative pathology in APP tg mice that was associated with improved water maze performance. It is worth noting that the local levels of the LV-driven transgene expression are relatively low and it is unclear if much higher levels of expression for a long time might have undesired side effects. Future studies will be needed to address this issue.
In conclusion, these data support the possibility that long-term NEP gene therapy improves behavioral and neurodegenerative pathology by reducing intracellular Aβ and support the potential for NEP augmentation in the treatment of AD.
Preparation of lentiviral vectors
Design of LV constructs was described previously . We produced LV expressing NEP or NEPX (an inactive version, bearing a point mutation E585V) under the control of the CMV promoter, or empty vector (LV-empty) using a four-plasmid transfection system, as previously described [64–66]. Briefly, 293T cells were transfected with vector and packaging plasmids, the supernatants collected and vectors concentrated by centrifugation. The LV titers were estimated by measuring the amount of HIV p24 gag antigen by ELISA (Perkin Elmer Life Science, Boston, MA) (100,000 TU/ng p24) or by flow cytometry using a NEP-specific antibody (56C6, Research Diagnostics, Inc., Concord, MA).
Transgenic mouse generation and intracerebral injections of lentiviral vectors
For this study we used tg mice expressing the mutant human amyloid precursor protein (hAPPV717F/K670M/N671L) under the control of the platelet derived growth factor promoter (PDAPP minigene) . This line (J9M) of APP tg mice was selected because these mice express moderate levels of APP/Aβ and display neurodegenerative pathology and behavioral deficits associated with Aβ1–42 production . For this purpose, 6-month old APP tg mice (n = 24) received bilateral injections with 2 μl of the LV preparations (1.5 × 107 TU) into the frontal cortex and hippocampus (using a 5 μl Hamilton syringe, 0.25 μl/min). Mice received bilateral injections with LV-NEP (n = 8), LV-NEPX (inactive) (n = 8), or empty LV vector (LV-empty) alone (n = 8). Six months post-injection (12 months old) mice were tested in the water maze.
Water maze testing
As previously described , in order to evaluate the functional effects of long LV-NEP treatment in mice, groups of APP tg animals were tested in the water maze. For this purpose, a pool (diameter 180 cm) was filled with opaque water (24°C) and mice were first trained to locate a visible platform (days 1–3) and then a submerged hidden platform (days 4–7) in three daily trials 2–3 min apart. Mice that failed to find the hidden platform within 90 s were placed on it for 30 s. The same platform location was used for all sessions and all mice. The starting point at which each mouse was placed into the water was changed randomly between two alternative entry points located at a similar distance from the platform. On day 8, another visible platform trial was performed to exclude differences in motivation and fatigue. Time to reach the platform (latency), path length, and swim speed were recorded with a Noldus Instruments EthoVision video tracking system (San Diego Instruments, San Diego, CA) set to analyze two samples per second. All experiments described were approved by the animal subjects committee at the University of California at San Diego (UCSD) and were performed according to NIH recommendations for animal use.
Brains were removed and divided sagittaly. One hemibrain was post-fixed in phosphate-buffered 4% paraformaldehyde (pH 7.4) at 4°C for 48 hrs and sectioned at 40 μm with a Vibratome 2000 (Leica, Germany), while the other hemibrain was snap-frozen and stored at -70°C for immunoblot analysis.
Analysis of APP/Aβ levels by immunoblot
For Western blot analysis, 20 μg per lane of cytosolic and particulate fractions, assayed by the BCA method (Pierce Biotechnology, Rockford, IL), were loaded into 4–12% SDS-PAGE gels and blotted onto polyvinylidene fluoride (PVDF) membranes. Blots were incubated with antibodies against APP/Aβ (mouse monoclonal, clone 6E10, Signet Laboratories, Dedham, MA or rabbit polyclonal, clone CT15, personal gift of E. Koo) and NEP (mouse monoclonal, clone CD10, Abcam, Cambridge, MA) followed by secondary antibodies tagged with horseradish peroxidase (HRP, Santa Cruz Biotechnology, Inc.) and visualized by enhanced chemiluminescence and analyzed with a Versadoc XL imaging apparatus (BioRad, Hercules, CA). Analysis of actin levels was used as a loading control.
Analysis of NEP activity
The proteolytic activity of NEP was measured as previously described  using the substrate 3-dansyl-D-Ala-Gly-p-(nitro)-Phe-Gly (DAGNPG; Sigma). Cell lysate was incubated with 50 μM DAGNPG and 1 μM captopril (to inhibit any ACE cleavage of DAGNPG) in a volume of 200 μl at 37°C. Reactions were stopped by heating samples to 100°C for 5 min, then centrifuging. The supernatant was diluted into 50 mM Tris (pH 7.4) and fluorescence determined using a Victor2 multilabel plate reader (excitation 342 nm; emission 562 nm).
Analysis of Aβ levels and amyloid plaque load by immunocytochemistry
To evaluate the amyloid plaque load, briefly as previously described, vibratome sections were incubated overnight at 4°C with the mouse monoclonal antibody against Aβ (clone 6E10, 1:1000, Signet Laboratories, Dedham, MA) followed by fluorescein isothiocyanate (FITC)-conjugated anti-mouse IgG (Vector Laboratories, Burlingame, CA). The FITC-labelled sections were imaged with the laser scanning confocal microscope (LSCM, MRC1024, BioRad) as described previously . Digitized images were analyzed with the NIH Image 1.43 program to determine the percent area of the neuropil occupied by Aβ-immunoreactive deposits in the frontal cortex and hippocampus. To evaluate effects on intracellular Aβ, sections were immunolabelled with the mouse monoclonal antibody against Aβ (clone 4G8; 1:600, Senetek, Napa, CA) and with the antibody against the N-terminus of Aβ (aa 1–16; clone 82E1; Immunobiological Laboratorie Co. Gunma, Japan) followed by incubation with secondary biotinylated anti-mouse IgG, followed by ABC and DAB. Sections were transferred to SuperFrost slides (Fisher Scientific, Tustin, CA) and mounted under glass coverslips with anti-fading media (Vector Laboratories). All sections were processed under the same standardized conditions. Three immunolabelled sections were analyzed per mouse and the average of individual measurements was used to calculate group means.
Analysis NEP expression, double immunolabelling and neurodegeneration
To verify the expression levels of NEP, vibratome sections were immunolabelled with a monoclonal antibody against NEP (CD10, 1:10,000, Abcam, Cambridge, MA) detected with the Tyramide Signal Amplification™-Direct (Red) system (1:100, NEN Life Sciences, Boston, MA). To evaluate the co-localization between APP and NEP, or the intracellular distribution of APP and Aβ double immunocytochemical analysis was performed as previously described . For this purpose, vibratome sections were immunolabelled with a monoclonal antibody against NEP (1:10,000, Abcam) or Aβ (clone 4G8; 1:600, Senetek, Napa, CA) detected with the Tyramide Signal Amplification™-Direct (Red) system (1:100, NEN Life Sciences, Boston, MA) and the mouse monoclonal antibodies against human APP (1:500, 8E5 clone, Elan Pharmaceuticals, South San Francisco, CA) detected with FITC-conjugated secondary antibodies (1:75, Vector Laboratories) . All sections were processed simultaneously under the same conditions and experiments were performed twice to assess reproducibility. Sections were imaged with a Zeiss 63× (N.A. 1.4) objective on an Axiovert 35 microscope (Zeiss, Germany) with an attached MRC1024 LSCM system (BioRad) . To confirm the specificity of primary antibodies, control experiments were performed where sections were incubated overnight in the absence of primary antibody (deleted) or preimmune serum and primary antibody alone.
The integrity of the neuronal structure was evaluated as previously described [68, 70]; briefly, blind-coded, 40-μm thick vibratome sections from mouse brains fixed in 4% paraformaldehyde were immunolabelled with the mouse monoclonal antibodies against synaptophysin (synaptic marker, 1:20, Chemicon, Temecula, CA) and microtubule associated protein-2 (MAP2, dendritic marker, 1:40, Chemicon). After overnight incubation with the MAP2 and synaptophysin, sections were incubated with FITC-conjugated horse anti-mouse IgG secondary antibody (1:75, Vector Laboratories), transferred to SuperFrost slides (Fisher Scientific) and mounted under glass coverslips with anti-fading media (Vector Laboratories). All sections were processed under the same standardized conditions. The immunolabelled blind-coded sections were serially imaged with the LSCM (MRC1024, BioRad) and analyzed with the Image 1.43 program (NIH), as previously described [71, 72]. For each mouse, a total of 3 sections were analyzed and for each section, 4 fields in the frontal cortex and hippocampus were examined. For synaptophysin and MAP2, results were expressed as percent area of the neuropil occupied by immunoreactive terminals and dendrites.
Analyses were carried out with the StatView 5.0 program (SAS Institute Inc., Cary, NC). Differences among means were assessed by one-way ANOVA with post-hoc Dunnett's or Tukey-Kramer tests. All values in the figures are expressed as means ± SEM. Comparisons between 2 groups were done with the unpaired two-tailed Student's t-test. Correlation studies were carried out by simple regression analysis and the null hypothesis was rejected at the 0.05 level. To evaluate the effects of interactions between genotype and treatment 2-way ANOVA was used with the SuperANOVA software package (SAS Institute Inc., Cary, NC).
This work was supported by NIH grants AG18440, AG022074, and AG10435. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
- Ashford JW: APOE genotype effects on Alzheimer's disease onset and epidemiology. J Mol Neurosci. 2004, 23 (3): 157-165.View ArticlePubMedGoogle Scholar
- Masliah E: The role of synaptic proteins in Alzheimer's disease. Ann N Y Acad Sci. 2000, 924: 68-75.View ArticlePubMedGoogle Scholar
- Selkoe DJ: Alzheimer's disease is a synaptic failure. Science. 2002, 298 (5594): 789-791.View ArticlePubMedGoogle Scholar
- DeKosky S, Scheff S: Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. AnnNeurol. 1990, 27: 457-464.Google Scholar
- Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L: High-level neuronal expression of abeta 1–42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000, 20 (11): 4050-4058.PubMedGoogle Scholar
- Selkoe DJ: Amyloid beta-protein precursor: new clues to the genesis of Alzheimer's disease. Curr Opin Neurobiol. 1994, 4 (5): 708-716.View ArticlePubMedGoogle Scholar
- Glabe CC: Amyloid accumulation and pathogensis of Alzheimer's disease: significance of monomeric, oligomeric and fibrillar Abeta. Subcell Biochem. 2005, 38: 167-177.View ArticlePubMedGoogle Scholar
- Klein WL, Krafft GA, Finch CE: Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum?. Trends Neurosci. 2001, 24 (4): 219-224.View ArticlePubMedGoogle Scholar
- Selkoe DJ: Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res. 2008, 192 (1): 106-113.PubMed CentralView ArticlePubMedGoogle Scholar
- Cuello AC, Canneva F: Impact of intracellular beta-amyloid in transgenic animals and cell models. Neurodegener Dis. 2008, 5 (3–4): 146-148.View ArticlePubMedGoogle Scholar
- Cuello AC: Intracellular and extracellular Abeta, a tale of two neuropathologies. Brain Pathol. 2005, 15 (1): 66-71.View ArticlePubMedGoogle Scholar
- LaFerla FM, Green KN, Oddo S: Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci. 2007, 8 (7): 499-509.View ArticlePubMedGoogle Scholar
- Lee EK, Park YW, Shin DY, Mook-Jung I, Yoo YJ: Cytosolic amyloid-beta peptide 42 escaping from degradation induces cell death. Biochem Biophys Res Commun. 2006, 344 (2): 471-477.View ArticlePubMedGoogle Scholar
- Spencer B, Rockenstein E, Crews L, Marr R, Masliah E: Novel strategies for Alzheimer's disease treatment. Expert Opin Biol Ther. 2007, 7 (12): 1853-1867.View ArticlePubMedGoogle Scholar
- Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL, Wong PC: BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat Neurosci. 2001, 4 (3): 233-234.View ArticlePubMedGoogle Scholar
- Luo JJ, Wallace W, Riccioni T, Ingram DK, Roth GS, Kusiak JW: Death of PC12 cells and hippocampal neurons induced by adenoviral-mediated FAD human amyloid precursor protein gene expression. J Neurosci Res. 1999, 55 (5): 629-642.View ArticlePubMedGoogle Scholar
- Schapira AH: Etiology of Parkinson's disease. Neurology. 2006, 66 (10 Suppl 4): S10-23.View ArticlePubMedGoogle Scholar
- Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, et al: Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999, 286 (5440): 735-741.View ArticlePubMedGoogle Scholar
- Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey HF, Frigon N, Hong J, et al: Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature. 1999, 402 (6761): 537-540.View ArticlePubMedGoogle Scholar
- Howell S, Nalbantoglu J, Crine P: Neutral endopeptidase can hydrolyze beta-amyloid(1–40) but shows no effect on beta-amyloid precursor protein metabolism. Peptides. 1995, 16 (4): 647-652.View ArticlePubMedGoogle Scholar
- Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, Kawashima-Morishima M, Lee HJ, Hama E, Sekine-Aizawa Y, et al: Identification of the major Abeta1–42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med. 2000, 6 (2): 143-150.View ArticlePubMedGoogle Scholar
- Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, Gerard C, Hama E, Lee HJ, Saido TC: Metabolic regulation of brain Abeta by neprilysin. Science. 2001, 292 (5521): 1550-1552.View ArticlePubMedGoogle Scholar
- Akiyama H, Kondo H, Ikeda K, Kato M, McGeer PL: Immunohistochemical localization of neprilysin in the human cerebral cortex: inverse association with vulnerability to amyloid beta-protein (Abeta) deposition. Brain Res. 2001, 902 (2): 277-281.View ArticlePubMedGoogle Scholar
- Reilly CE: Neprilysin content is reduced in Alzheimer brain areas. J Neurol. 2001, 248 (2): 159-160.View ArticlePubMedGoogle Scholar
- Caccamo A, Oddo S, Sugarman MC, Akbari Y, LaFerla FM: Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders. Neurobiol Aging. 2005, 26 (5): 645-654.View ArticlePubMedGoogle Scholar
- Yasojima K, McGeer EG, McGeer PL: Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain. Brain Res. 2001, 919 (1): 115-121.View ArticlePubMedGoogle Scholar
- Yasojima K, Akiyama H, McGeer EG, McGeer PL: Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of beta-amyloid peptide. Neurosci Lett. 2001, 297 (2): 97-100.View ArticlePubMedGoogle Scholar
- Apelt J, Ach K, Schliebs R: Aging-related down-regulation of neprilysin, a putative beta-amyloid-degrading enzyme, in transgenic Tg2576 Alzheimer-like mouse brain is accompanied by an astroglial upregulation in the vicinity of beta-amyloid plaques. Neurosci Lett. 2003, 339 (3): 183-186.View ArticlePubMedGoogle Scholar
- Maruyama M, Higuchi M, Takaki Y, Matsuba Y, Tanji H, Nemoto M, Tomita N, Matsui T, Iwata N, Mizukami H, et al: Cerebrospinal fluid neprilysin is reduced in prodromal Alzheimer's disease. Ann Neurol. 2005, 57 (6): 832-842.View ArticlePubMedGoogle Scholar
- Wang DS, Lipton RB, Katz MJ, Davies P, Buschke H, Kuslansky G, Verghese J, Younkin SG, Eckman C, Dickson DW: Decreased neprilysin immunoreactivity in Alzheimer disease, but not in pathological aging. J Neuropathol Exp Neurol. 2005, 64 (5): 378-385.View ArticlePubMedGoogle Scholar
- Oda M, Morino H, Maruyama H, Terasawa H, Izumi Y, Torii T, Sasaki K, Nakamura S, Kawakami H: Dinucleotide repeat polymorphisms in the neprilysin gene are not associated with sporadic Alzheimer's disease. Neurosci Lett. 2002, 320 (1–2): 105-107.View ArticlePubMedGoogle Scholar
- Sodeyama N, Mizusawa H, Yamada M, Itoh Y, Otomo E, Matsushita M: Lack of association of neprilysin polymorphism with Alzheimer's disease and Alzheimer's disease-type neuropathological changes. J Neurol Neurosurg Psychiatry. 2001, 71 (6): 817-818.PubMed CentralView ArticlePubMedGoogle Scholar
- Shi J, Zhang S, Tang M, Ma C, Zhao J, Li T, Liu X, Sun Y, Guo Y, Han H, et al: Mutation screening and association study of the neprilysin gene in sporadic Alzheimer's disease in Chinese persons. J Gerontol A Biol Sci Med Sci. 2005, 60 (3): 301-306.View ArticlePubMedGoogle Scholar
- Helisalmi S, Hiltunen M, Vepsalainen S, Iivonen S, Mannermaa A, Lehtovirta M, Koivisto AM, Alafuzoff I, Soininen H: Polymorphisms in neprilysin gene affect the risk of Alzheimer's disease in Finnish patients. J Neurol Neurosurg Psychiatry. 2004, 75 (12): 1746-1748.PubMed CentralView ArticlePubMedGoogle Scholar
- Sakai A, Ujike H, Nakata K, Takehisa Y, Imamura T, Uchida N, Kanzaki A, Yamamoto M, Fujisawa Y, Okumura K, et al: Association of the Neprilysin gene with susceptibility to late-onset Alzheimer's disease. Dement Geriatr Cogn Disord. 2004, 17 (3): 164-169.View ArticlePubMedGoogle Scholar
- Clarimon J, Munoz FJ, Boada M, Tarraga L, Sunyer J, Bertranpetit J, Comas D: Possible increased risk for Alzheimer's disease associated with neprilysin gene. J Neural Transm. 2003, 110 (6): 651-657.View ArticlePubMedGoogle Scholar
- Dolev I, Michaelson DM: A nontransgenic mouse model shows inducible amyloid-beta (Abeta) peptide deposition and elucidates the role of apolipoprotein E in the amyloid cascade. Proc Natl Acad Sci USA. 2004, 101 (38): 13909-13914.PubMed CentralView ArticlePubMedGoogle Scholar
- Marr RA, Rockenstein E, Mukherjee A, Kindy MS, Hersh LB, Gage FH, Verma IM, Masliah E: Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J Neurosci. 2003, 23 (6): 1992-1996.PubMedGoogle Scholar
- Iwata N, Mizukami H, Shirotani K, Takaki Y, Muramatsu S, Lu B, Gerard NP, Gerard C, Ozawa K, Saido TC: Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-beta peptide in mouse brain. J Neurosci. 2004, 24 (4): 991-998.View ArticlePubMedGoogle Scholar
- Hemming ML, Patterson M, Reske-Nielsen C, Lin L, Isacson O, Selkoe DJ: Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease. PLoS Med. 2007, 4 (8): e262.PubMed CentralView ArticlePubMedGoogle Scholar
- Rockenstein E, Torrance M, Adame A, Mante M, Bar-on P, Rose JB, Crews L, Masliah E: Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. J Neurosci. 2007, 27 (8): 1981-1991.View ArticlePubMedGoogle Scholar
- Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, Sun X, Frosch MP, Selkoe DJ: Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron. 2003, 40 (6): 1087-1093.View ArticlePubMedGoogle Scholar
- Mohajeri MH, Wollmer MA, Nitsch RM: Abeta 42-induced increase in neprilysin is associated with prevention of amyloid plaque formation in vivo. J Biol Chem. 2002, 277 (38): 35460-35465.View ArticlePubMedGoogle Scholar
- Saito T, Iwata N, Tsubuki S, Takaki Y, Takano J, Huang SM, Suemoto T, Higuchi M, Saido TC: Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation. Nat Med. 2005, 11 (4): 434-439.View ArticlePubMedGoogle Scholar
- Lazarov O, Robinson J, Tang YP, Hairston IS, Korade-Mirnics Z, Lee VM, Hersh LB, Sapolsky RM, Mirnics K, Sisodia SS: Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell. 2005, 120 (5): 701-713.View ArticlePubMedGoogle Scholar
- Farris W, Schutz SG, Cirrito JR, Shankar GM, Sun X, George A, Leissring MA, Walsh DM, Qiu WQ, Holtzman DM, et al: Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. Am J Pathol. 2007, 171 (1): 241-251.PubMed CentralView ArticlePubMedGoogle Scholar
- Huang SM, Mouri A, Kokubo H, Nakajima R, Suemoto T, Higuchi M, Staufenbiel M, Noda Y, Yamaguchi H, Nabeshima T, et al: Neprilysin-sensitive Synapse-associated Amyloid-beta Peptide Oligomers Impair Neuronal Plasticity and Cognitive Function. J Biol Chem. 2006, 281 (26): 17941-17951.View ArticlePubMedGoogle Scholar
- Marr RA, Guan H, Rockenstein E, Kindy M, Gage FH, Verma I, Masliah E, Hersh LB: Neprilysin regulates amyloid Beta peptide levels. J Mol Neurosci. 2004, 22 (1–2): 5-11.View ArticlePubMedGoogle Scholar
- Hong CS, Goins WF, Goss JR, Burton EA, Glorioso JC: Herpes simplex virus RNAi and neprilysin gene transfer vectors reduce accumulation of Alzheimer's disease-related amyloid-beta peptide in vivo. Gene Ther. 2006, 13 (14): 1068-1079.View ArticlePubMedGoogle Scholar
- Nagy Z, Esiri M, Jobst K, Morris J, King E, McDonald B, Litchfield S, Smith A, Barneston L, Smith A: Relative roles of plaques and tangles in the dementia of Alzheimer's disease: correlations using three sets of neuropathological criteria. Dementia. 1995, 6: 21-31.PubMedGoogle Scholar
- Sloane JA, Pietropaolo MF, Rosene DL, Moss MB, Peters A, Kemper T, Abraham CR: Lack of correlation between plaque burden and cognition in the aged monkey. Acta Neuropathol. 1997, 94 (5): 471-478.View ArticlePubMedGoogle Scholar
- Rockenstein E, Mallory M, Mante M, Sisk A, Masliah E: Early formation of mature amyloid-b proteins deposits in a mutant APP transgenic model depends on levels of Ab1–42. J neurosci Res. 2001, 66: 573-582.View ArticlePubMedGoogle Scholar
- Hsia AY, Masliah E, McConlogue L, Yu G-Q, Tatsuno G, Hu K, Kholodenko D, Malenka RC, Nicoll RA, Mucke L: Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. ProcNatlAcadSciUSA. 1999, 96: 3228-3233.View ArticleGoogle Scholar
- El-Amouri SS, Zhu H, Yu J, Marr R, Verma IM, Kindy MS: Neprilysin: an enzyme candidate to slow the progression of Alzheimer's disease. Am J Pathol. 2008, 172 (5): 1342-1354.PubMed CentralView ArticlePubMedGoogle Scholar
- Borchelt D, Thinakaran G, Eckman C, Lee M, Davenport F, Ratovitsky T, Prada C, Kim G, Seekins S, Yager D: Familial Alzheimer's disease-linked presenilin 1 variants elevate Aβ1–42/1–40 ratio in vitro and in vivo. Neuron. 1996, 17: 1005-1013.View ArticlePubMedGoogle Scholar
- Huang F, Buttini M, Wyss-Coray T, McConlogue L, Kodama T, Pitas RE, Mucke L: Elimination of the class A scavenger receptor does not affect amyloid plaque formation or neurodegeneration in transgenic mice expressing human amyloid protein precursors. Am J Pathol. 1999, 155 (5): 1741-1747.PubMed CentralView ArticlePubMedGoogle Scholar
- Forloni G, Chiesa R, Smiroldo S, Verga L, Salmona M, Tagliavini F, Angeretti N: Apoptosis mediated neurotoxicity induced by chronic application of β amyloid fragment 25–35. NeuroReport. 1993, 4: 523-526.View ArticlePubMedGoogle Scholar
- Echeverria V, Cuello AC: Intracellular A-beta amyloid, a sign for worse things to come?. Mol Neurobiol. 2002, 26 (2–3): 299-316.View ArticlePubMedGoogle Scholar
- Iijima-Ando K, Hearn SA, Granger L, Shenton C, Gatt A, Chiang HC, Hakker I, Zhong Y, Iijima K: Overexpression of neprilysin reduces alzheimer amyloid-beta42 (Abeta42)-induced neuron loss and intraneuronal Abeta42 deposits but causes a reduction in cAMP-responsive element-binding protein-mediated transcription, age-dependent axon pathology, and premature death in Drosophila. J Biol Chem. 2008, 283 (27): 19066-19076.PubMed CentralView ArticlePubMedGoogle Scholar
- Turner AJ, Isaac RE, Coates D: The neprilysin (NEP) family of zinc metalloendopeptidases: genomics and function. Bioessays. 2001, 23 (3): 261-269.View ArticlePubMedGoogle Scholar
- Russo R, Borghi R, Markesbery W, Tabaton M, Piccini A: Neprylisin decreases uniformly in Alzheimer's disease and in normal aging. FEBS Lett. 2005, 579 (27): 6027-6030.View ArticlePubMedGoogle Scholar
- Miners JS, Van Helmond Z, Chalmers K, Wilcock G, Love S, Kehoe PG: Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy. J Neuropathol Exp Neurol. 2006, 65 (10): 1012-1021.View ArticlePubMedGoogle Scholar
- Hersh LB: Peptidases, proteases and amyloid beta-peptide catabolism. Curr Pharm Des. 2003, 9 (6): 449-454.View ArticlePubMedGoogle Scholar
- Miyoshi H, Blomer U, Takahashi M, Gage FH, Verma IM: Development of a self-inactivating lentivirus vector. J Virol. 1998, 72 (10): 8150-8157.PubMed CentralPubMedGoogle Scholar
- Tiscornia G, Singer O, Verma IM: Design and cloning of lentiviral vectors expressing small interfering RNAs. Nat Protoc. 2006, 1 (1): 234-240.View ArticlePubMedGoogle Scholar
- Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini L: A third-generation lentivirus vector with a conditional packaging system. J Virol. 1998, 72 (11): 8463-8471.PubMed CentralPubMedGoogle Scholar
- Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, Mucke L: beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci USA. 2001, 98 (21): 12245-12250.PubMed CentralView ArticlePubMedGoogle Scholar
- Rockenstein E, Mante M, Alford M, Adame A, Crews L, Hashimoto M, Esposito L, Mucke L, Masliah E: High beta-secretase activity elicits neurodegeneration in transgenic mice despite reductions in amyloid-beta levels: implications for the treatment of Alzheimer disease. J Biol Chem. 2005, 280 (38): 32957-32967.View ArticlePubMedGoogle Scholar
- Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara , Sisk A, Mucke L: Dopaminergic loss and inclusion body formation in alpha-synuclein mice: Implications for neurodegenerative disorders. Science. 2000, 287: 1265-1269.View ArticlePubMedGoogle Scholar
- Rockenstein E, Schwach G, Ingolic E, Adame A, Crews L, Mante M, Pfragner R, Schreiner E, Windisch M, Masliah E: Lysosomal pathology associated with alpha-synuclein accumulation in transgenic models using an eGFP fusion protein. J Neurosci Res. 2005, 80 (2): 247-259.View ArticlePubMedGoogle Scholar
- Toggas S, Masliah E, Rockenstein E, Mucke L: Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature. 1994, 367: 188-193.View ArticlePubMedGoogle Scholar
- Mucke L, Abraham C, Ruppe M, Rockenstein E, Toggas S, Alford M, Masliah E: Protection against HIV-1 gp120-induced brain damage by neuronal overexpression of human amyloid precursor protein (hAPP). JExpMed. 1995, 181: 1551-1556.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.